Shares of Cellectis S.A. (NASDAQ:CLLS – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the […]